Literature DB >> 20724374

Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry.

Carmen Suárez1, Uwe Zeymer, Tobias Limbourg, Iris Baumgartner, Patrice Cacoub, Don Poldermans, Joachim Röther, Deepak L Bhatt, Ph Gabriel Steg.   

Abstract

Cardiovascular event rates have been shown to increase substantially with the number of symptomatic disease locations. We sought to assess the risk profile, management and subsequent event rates of polyvascular disease patients. Consecutive outpatients were assessed for atherosclerotic risk factors and medications in the REACH Registry. A total of 19,117 symptomatic patients in Europe completed a 2-year follow-up: 77.2% with single arterial bed disease (coronary artery or cerebrovascular or peripheral arterial disease) and 22.8% with polyvascular disease (>/= 1 disease location). Polyvascular disease patients were older (68.5 +/- 9.4 vs 66.3 +/- 9.9 years, p < 0.0001), more often current or former smokers (64.9% vs 58.7%, p < 0.0001), and more often suffered from hypertension (59.5% vs 46.6%, p < 0.0001) and diabetes (34.5% vs 25.9%, p < 0.0001) than single arterial bed disease patients. Despite more intense medical therapy, risk factors (smoking, hypertension, low fasting glucose, and low fasting total cholesterol) were less often controlled in polyvascular disease patients. This was associated with substantially more events over 2 years compared with single arterial bed disease patients (cMACCE [cardiovascular death/non-fatal stroke/non-fatal MI] odds ratio, 1.63 [95% CI, 1.45-1.83], p < 0.0001). In conclusion, polyvascular disease patients have more cardiovascular risk factors, and the prognosis for these patients is significantly worse than for patients with single arterial bed disease. This suggests a need to improve detection and consequent medical treatment of polyvascular disease.

Entities:  

Mesh:

Year:  2010        PMID: 20724374     DOI: 10.1177/1358863X10373299

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  20 in total

Review 1.  The association between B vitamins supplementation and adverse cardiovascular events: a meta-analysis.

Authors:  Wen-Feng Li; Dan-Dan Zhang; Ji-Tian Xia; Shan-Fan Wen; Jun Guo; Zi-Cheng Li
Journal:  Int J Clin Exp Med       Date:  2014-08-15

Review 2.  Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease.

Authors:  Davide Capodanno; Mark Alberts; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2016-08-04       Impact factor: 32.419

Review 3.  Primary and Novel Lipid-Lowering Therapies to Reduce Risk in Patients With Peripheral Arterial Disease.

Authors:  Alicia Chionchio; Andrew Galmer; Benjamin Hirsh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-12-17

Review 4.  The myth of 'stable' coronary artery disease.

Authors:  Keith A A Fox; Marco Metra; João Morais; Dan Atar
Journal:  Nat Rev Cardiol       Date:  2019-07-29       Impact factor: 32.419

Review 5.  Successful Peripheral Vascular Intervention in Patients with High-risk Comorbidities or Lesion Characteristics.

Authors:  E Hope Weissler; J Antonio Gutierrez; Manesh R Patel; Rajesh V Swaminathan
Journal:  Curr Cardiol Rep       Date:  2021-03-05       Impact factor: 2.931

6.  Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.

Authors:  Marc D Samsky; Robert J Mentz; Amanda Stebbins; Yuliya Lokhnygina; Aaron W Aday; Neha J Pagidipati; W Schuyler Jones; Brian G Katona; Manesh R Patel; Rury R Holman; Adrian F Hernandez; Jorge Antonio Gutierrez
Journal:  Atherosclerosis       Date:  2021-11-01       Impact factor: 5.162

7.  Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial.

Authors:  J Antonio Gutierrez; Hillary Mulder; W Schuyler Jones; Frank W Rockhold; Iris Baumgartner; Jeffrey S Berger; Juuso I Blomster; F Gerry R Fowkes; Peter Held; Brian G Katona; Kenneth W Mahaffey; Lars Norgren; William R Hiatt; Manesh R Patel
Journal:  JAMA Netw Open       Date:  2018-11-02

8.  Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.

Authors:  Saskia H Meves; Thomas Hummel; Heinz G Endres; Nora Mayböck; Andreas F C Kaiser; Kay D Schröder; Katja Rüdiger; Ursula Overbeck; Achim Mumme; Andreas Mügge; Horst Neubauer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

9.  Impact of Multivascular Disease on Cardiovascular Mortality and Morbidity in Patients Receiving Hemodialysis: Ten-Year Outcomes of the Q-Cohort Study.

Authors:  Shigeru Tanaka; Toshiaki Nakano; Hiroto Hiyamuta; Masatomo Taniguchi; Masanori Tokumoto; Kosuke Masutani; Hiroaki Ooboshi; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  J Atheroscler Thromb       Date:  2020-07-17       Impact factor: 4.928

10.  Serum total bilirubin concentration in patients with type 2 diabetes as a possible biomarker of polyvascular disease.

Authors:  Takeshi Nishimura; Masami Tanaka; Risa Sekioka; Hiroshi Itoh
Journal:  Diabetol Int       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.